These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37632124)

  • 1. Implementation and early outcomes of a telehealth visit model to deliver tecovirimat for mpox infection in New York City.
    Chan J; DiTullio DJ; Pagan Pirallo P; Foote M; Knutsen D; Kottkamp AC; McPherson TD; Mukherjee V; Pitts R; Wallach A; Wong M; Mazo D; Mgbako O
    J Telemed Telecare; 2023 Aug; ():1357633X231194796. PubMed ID: 37632124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Navigating the expanded access investigational new drug protocol for tecovirimat: lessons learned from a public-private hospital partnership during the 2022 NYC mpox outbreak.
    Mgbako O; Chan J; Pitts RA; DiLorenzo MA; Knutsen D; Mazo D
    Antimicrob Steward Healthc Epidemiol; 2023; 3(1):e110. PubMed ID: 37502253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System.
    Vo C; Zomorodi R; Silvera R; Bartram L; Lugo LA; Kojic E; Urbina A; Aberg J; Sigel K; Chasan R; Patel G
    Open Forum Infect Dis; 2023 Nov; 10(11):ofad552. PubMed ID: 38023539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Distribution of Tecovirimat During the Peak of the Mpox Outbreak - Los Angeles County, June 2022-January 2023.
    O'Neil MJ; Archer R; Danza P; Fisher R; Bagwell DA; Younis I; Kulkarni S; Rubin Z; Kim M; Balter S; Terashita D; Kim J; Singhal R; Hancz D; Gausche-Hill M; Shah NK
    MMWR Morb Mortal Wkly Rep; 2024 Jun; 73(24):546-550. PubMed ID: 38900699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tecovirimat Treatment of People With HIV During the 2022 Mpox Outbreak : A Retrospective Cohort Study.
    McLean J; Stoeckle K; Huang S; Berardi J; Gray B; Glesby MJ; Zucker J
    Ann Intern Med; 2023 May; 176(5):642-648. PubMed ID: 37126820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report.
    Martinez AE; Frattaroli P; Vu CA; Paniagua L; Mintz J; Bravo-Gonzalez A; Zamudio P; Barco A; Rampersad A; Lichtenberger P; Gonzales-Zamora JA
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Tecovirimat Treatment for Mpox Disease Among People With HIV.
    Aldred B; Lyles RH; Scott JY; Gromer DJ; Aldredge A; Workowski KA; Wiley Z; Titanji BK; Szabo B; Sheth AN; Rebolledo PA; Nguyen ML; Marconi VC; Kelley CF; Kandiah S; Kalapila A; Jacob JT; Hall B; Colasanti JA; Cartwright EJ; Cantos VD
    JAMA Intern Med; 2024 Mar; 184(3):275-279. PubMed ID: 38190312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022.
    O'Laughlin K; Tobolowsky FA; Elmor R; Overton R; O'Connor SM; Damon IK; Petersen BW; Rao AK; Chatham-Stephens K; Yu P; Yu Y;
    MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(37):1190-1195. PubMed ID: 36107794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mpox in the New York metropolitan area, Summer 2022.
    Gnanaprakasam R; Keller M; Glassman R; El-Khoury MY; Chen DS; Feola N; Feldman J; Chaturvedi V
    J Med Virol; 2023 Apr; 95(4):e28699. PubMed ID: 36951318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mpox in Children: 3 Cases.
    Frantzis I; Ungar SP; Soma VL; Knutsen D; Mazo D; Zucker J
    Pediatrics; 2024 Jan; 153(2):. PubMed ID: 38239109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical Elements of an Mpox Vaccination Model at the Largest Public Health Hospital System in the United States.
    Piccolo AJL; Chan J; Cohen GM; Mgbako O; Pitts RA; Postelnicu R; Wallach A; Mukherjee V
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of a Tertiary Level Safety Net Hospital in New York City's 2022 Mpox Outbreak.
    Lo Piccolo AJ; Wallach A; McPherson TD; Mgbako O; Fagan I; Pitts RA; Klinger A; Foote M; Garcia EA; Zucker JE; Chan J; Bails DB; Cohen GM; Tennill PA; Wong M; Mukherjee V
    Health Secur; 2023; 21(2):146-155. PubMed ID: 36862506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Mpox Among People With Advanced Human Immunodeficiency Virus Receiving Prolonged Tecovirimat in New York City.
    Garcia EA; Foote MMK; McPherson TD; Lash MK; Bosompem AN; Bouscaren A; Chan J; DiLorenzo MA; Feihel D; Fowler RC; Gandhi V; Jenny-Avital ER; Kopping EJ; Mazo D; McLean J; Mgbako O; Sayegh MN; Shaw RN; Su M; Meissner JS; Wang JC; Wen W; Winters JC; Zeana CB; Zucker J; Wong M
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae294. PubMed ID: 38868307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and viral dynamics of tecovirimat in patients with MPOX: A multicenter open-label, double-arm trial in Japan.
    Akiyama Y; Morioka S; Tsuzuki S; Yoshikawa T; Yamato M; Nakamura H; Shimojima M; Takakusaki M; Saito S; Takahashi K; Sanada M; Komatsubara M; Takebuchi K; Yamaguchi E; Suzuki T; Shimokawa K; Kurosu T; Kawahara M; Oishi K; Ebihara H; Ohmagari N
    J Infect Chemother; 2024 Jun; 30(6):488-493. PubMed ID: 38042298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Transition to Telehealth and the Digital Divide: Implications for Primary Care Access and Equity in a Post-COVID Era.
    Chang JE; Lai AY; Gupta A; Nguyen AM; Berry CA; Shelley DR
    Milbank Q; 2021 Jun; 99(2):340-368. PubMed ID: 34075622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CDC Domestic Mpox Response - United States, 2022-2023.
    McQuiston JH; Braden CR; Bowen MD; McCollum AM; McDonald R; Carnes N; Carter RJ; Christie A; Doty JB; Ellington S; Fehrenbach SN; Gundlapalli AV; Hutson CL; Kachur RE; Maitland A; Pearson CM; Prejean J; Quilter LAS; Rao AK; Yu Y; Mermin J
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):547-552. PubMed ID: 37200231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mpox Genital Lesions: A Large Single-center Experience With Intermediate Follow-up.
    Lee J; McLean J; Zucker J; Brandes S; Joice G
    J Urol; 2023 Sep; 210(3):510-516. PubMed ID: 37294043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of tecovirimat in subjects with Mpox.
    Tempestilli M; Mondi A; D'Avolio A; Forini O; Pinnetti C; Mazzotta V; Gagliardini R; Beccacece A; De Nicolò A; Faccendini P; Cimini E; Maggi F; Girardi E; Nicastri E; Boffito M; Vaia F; Antinori A
    Int J Antimicrob Agents; 2024 Feb; 63(2):107068. PubMed ID: 38141836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection.
    Nguyen BT; Marc A; Suñer C; Marks M; Ubals M; Hernández-Rodríguez Á; Melendez MÁ; ; Hruby DE; Russo AT; Mentré F; Mitjà O; Grosenbach DW; Guedj J
    PLoS Biol; 2023 Dec; 21(12):e3002249. PubMed ID: 38127878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the Impact of Mpox on Sexual Health Clinical Services: A National Knowledge, Attitudes, and Practices Survey-United States, 2022.
    Schubert SL; Miele K; Quilter LAS; Agnew-Brune C; Coor A; Kachur R; Lewis F; Ard KL; Wendel K; Anderson T; Nagendra G; Tromble E;
    Sex Transm Dis; 2024 Jan; 51(1):38-46. PubMed ID: 37889929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.